Fig. 5

Curve fits and immunofluorescence (IF) validation for the two main classes of compounds targeting p60AmotL2-expressing cells. A and B Curve fits from the primary screen depicting the percentage of viability measured by CTG after 72 h of treatment with a 5-dose range of the respective inhibitors, RTKi (A) and BETi (B). Three representative compounds from each class are shown. The curve fits highlight the EC50 values of each inhibitor (represented by a gray line) and display the corresponding Drug Sensitivity Scores (DSS) for both p60AmotL2-expressing cells and their respective controls. C Immunofluorescence (IF) imaging validation in 2D after 72 h of treatment with Gefitinib (upper panel) and iBET151 (lower panel). Cell nuclei were stained with Hoechst 33342 (yellow). Red square is meant to highlight the difference in response to iBET151 of p60AmotL2-expressing cells when compared to controls. Scale bar = 500 μm